SORD-related peripheral neuropathy in a French and Swiss cohort: Clinical features, genetic analyses, and sorbitol dosages.
SORD
Charcot-Marie-Tooth
muscular atrophy
neuropathy
peripheral neuropathy
Journal
European journal of neurology
ISSN: 1468-1331
Titre abrégé: Eur J Neurol
Pays: England
ID NLM: 9506311
Informations de publication
Date de publication:
07 2023
07 2023
Historique:
revised:
27
02
2023
received:
25
11
2022
accepted:
14
03
2023
medline:
6
6
2023
pubmed:
22
3
2023
entrez:
21
3
2023
Statut:
ppublish
Résumé
Biallelic variants in SORD have been reported as one of the main recessive causes for hereditary peripheral neuropathies such as Charcot-Marie-Tooth disease type 2 (CMT2) and distal hereditary motor neuropathy (dHMN) resulting in lower limb (LL) weakness and muscular atrophy. In this study, phenotype and genotype landscapes of SORD-related peripheral neuropathies were described in a French and Swiss cohort. Serum sorbitol dosages were used to classify SORD variants. Patients followed at neuromuscular reference centres in France and Switzerland were ascertained. Sanger sequencing and next generation sequencing were performed to sequence SORD, and mass spectrometry was used to measure patients' serum sorbitol. Thirty patients had SORD peripheral neuropathy associating LL weakness with muscular atrophy, foot deformities (87%), and sometimes proximal LL weakness (20%) or distal upper limb weakness (50%). Eighteen had dHMN, nine had CMT2, and three had intermediate CMT. Most of them had a mild or moderate disease severity. Sixteen carried a homozygous c.757delG (p.Ala253Glnfs*27) variant, and 11 carried compound heterozygous variants, among which four variants were not yet reported: c.403C > G, c.379G > A, c.68_100 + 1dup, and c.850dup. Two unrelated patients with different origins carried a homozygous c.458C > A variant, and one patient carried a new homozygous c.786 + 5G > A variant. Mean serum sorbitol levels were 17.01 mg/L ± 8.9 SD for patients carrying SORD variants. This SORD-inherited peripheral neuropathy cohort of 30 patients showed homogeneous clinical presentation and systematically elevated sorbitol levels (22-fold) compared to controls, with both diagnostic and potential therapeutic implications.
Sections du résumé
BACKGROUND AND PURPOSE
Biallelic variants in SORD have been reported as one of the main recessive causes for hereditary peripheral neuropathies such as Charcot-Marie-Tooth disease type 2 (CMT2) and distal hereditary motor neuropathy (dHMN) resulting in lower limb (LL) weakness and muscular atrophy. In this study, phenotype and genotype landscapes of SORD-related peripheral neuropathies were described in a French and Swiss cohort. Serum sorbitol dosages were used to classify SORD variants.
METHODS
Patients followed at neuromuscular reference centres in France and Switzerland were ascertained. Sanger sequencing and next generation sequencing were performed to sequence SORD, and mass spectrometry was used to measure patients' serum sorbitol.
RESULTS
Thirty patients had SORD peripheral neuropathy associating LL weakness with muscular atrophy, foot deformities (87%), and sometimes proximal LL weakness (20%) or distal upper limb weakness (50%). Eighteen had dHMN, nine had CMT2, and three had intermediate CMT. Most of them had a mild or moderate disease severity. Sixteen carried a homozygous c.757delG (p.Ala253Glnfs*27) variant, and 11 carried compound heterozygous variants, among which four variants were not yet reported: c.403C > G, c.379G > A, c.68_100 + 1dup, and c.850dup. Two unrelated patients with different origins carried a homozygous c.458C > A variant, and one patient carried a new homozygous c.786 + 5G > A variant. Mean serum sorbitol levels were 17.01 mg/L ± 8.9 SD for patients carrying SORD variants.
CONCLUSIONS
This SORD-inherited peripheral neuropathy cohort of 30 patients showed homogeneous clinical presentation and systematically elevated sorbitol levels (22-fold) compared to controls, with both diagnostic and potential therapeutic implications.
Types de publication
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Pagination
2001-2011Informations de copyright
© 2023 The Authors. European Journal of Neurology published by John Wiley & Sons Ltd on behalf of European Academy of Neurology.
Références
Benquey T, Pion E, Cossée M, et al. A National French Consensus on gene list for the diagnosis of Charcot-Marie-tooth disease and related disorders using next-generation sequencing. Genes. 2022;13(2):318.
Morena J, Gupta A, Hoyle JC. Charcot-Marie-tooth: from molecules to therapy. Int J Mol Sci. 2019;20(14):3419.
Bacquet J, Stojkovic T, Boyer A, et al. Molecular diagnosis of inherited peripheral neuropathies by targeted next-generation sequencing: molecular spectrum delineation. BMJ Open. 2018;8(10):e021632.
Rossor AM, Kalmar B, Greensmith L, Reilly MM. The distal hereditary motor neuropathies. J Neurol Neurosurg Psychiatry. 2012;83(1):6-14.
Xie Y, Lin Z, Pakhrin PS, et al. Genetic and clinical features in 24 Chinese distal hereditary motor neuropathy families. Front Neurol. 2020;11:603003.
Cortese A, Zhu Y, Rebelo A, et al. Biallelic mutations in SORD cause a common and potentially treatable hereditary neuropathy with implications for diabetes. Nat Genet Mai. 2020;52(5):473-481.
Liu X, He J, Yilihamu M, Duan X, Fan D. Clinical and genetic features of biallelic mutations in SORD in a series of Chinese patients with Charcot-Marie-tooth and distal hereditary motor neuropathy. Front Neurol. 2021;12:733926.
Dong HL, Li JQ, Liu GL, Yu H, Wu ZY. Biallelic SORD pathogenic variants cause Chinese patients with distal hereditary motor neuropathy. NPJ Genomic Med. 2021;6:1.
Frasquet M, Rojas-García R, Argente-Escrig H, et al. Distal hereditary motor neuropathies: mutation spectrum and genotype-phenotype correlation. Eur J Neurol. 2021;28(4):1334-1343.
Laššuthová P, Mazanec R, Staněk D, et al. Biallelic variants in the SORD gene are one of the most common causes of hereditary neuropathy among Czech patients. Sci Rep. 2021;11:8443.
Yuan R, Ye Z, Zhang X, Xu L, He J. Evaluation of SORD mutations as a novel cause of Charcot-Marie-tooth disease. Ann Clin Transl Neurol. 2020;8(1):266-270.
Murphy SM, Herrmann DN, McDermott MP, et al. Reliability of the CMT neuropathy score (second version) in Charcot-Marie-tooth disease. J Peripher Nerv Syst. 2011;16(3):191-198.
Bernard E, Pegat A, Vallet AE, et al. Juvenile amyotrophic lateral sclerosis associated with biallelic c.757delG mutation of sorbitol dehydrogenase gene. Amyotroph Lateral Scler Front Degener. 2022;23(5-6):473-475.
Li F, Cousineau C, Xing G, et al. Development and validation of a quantitative ultra performance LC® hydrophilic interaction liquid chromatography MS/MS method to measure fructose and sorbitol in human plasma. Bioanalysis. 2019;11(5):407-425.
Kopanos C, Tsiolkas V, Kouris A, et al. VarSome: the human genomic variant search engine. Bioinformatics. 2019;35(11):1978-1980.
Richards S, Aziz N, Bale S, et al. Standards and guidelines for the interpretation of sequence variants: a joint consensus recommendation of the American College of Medical Genetics and Genomics and the Association for Molecular Pathology. Genet Med. 2015;17(5):405-424. https://doi.org/10.1038/gim.2015.30
Lek M, Karczewski KJ, Minikel EV, et al. Analysis of protein-coding genetic variation in 60,706 humans. Nature. 2016;536(7616):285-291.
Subréville M, Bonello-Palot N, Yahiaoui D, et al. Genotype-phenotype correlation in French patients with myelin protein zero gene-related inherited neuropathy. Eur J Neurol. 2021;28(9):2913-2921.
Grosz BR, Stevanovski I, Negri S, et al. Long read sequencing overcomes challenges in the diagnosis of SORD neuropathy. J Peripher Nerv Syst. 2022;27(2):120-126.
Preston GM, Calle RA. Elevated serum sorbitol and not fructose in type 2 diabetic patients. Biomark Insights. 2010;5:33-38.
Shetty HU, Holloway HW, Rapoport SI. Capillary gas chromatography combined with ion trap detection for quantitative profiling of polyols in cerebrospinal fluid and plasma. Anal Biochem. 1995;224(1):279-285.
Vanholder R, Smet RD, Glorieux G, et al. Review on uremic toxins: classification, concentration, and interindividual variability. Kidney Int. 2003;63(5):1934-1943.
Hwang JJ, Johnson A, Cline G, et al. Fructose levels are markedly elevated in cerebrospinal fluid compared to plasma in pregnant women. PLoS ONE. 2015;10(6):e0128582.
Boso F, Armirotti A, Taioli F, et al. Deoxysphingolipids as candidate biomarkers for a novel SPTLC1 mutation associated with HSAN-I. Neurol Genet. 2019;5(6):e365.
Oyama T, Miyasita Y, Watanabe H, Shirai K. The role of polyol pathway in high glucose-induced endothelial cell damages. Diabetes Res Clin Pract. 2006;73(3):227-234.
Sekiguchi K, Kohara N, Baba M, et al. Aldose reductase inhibitor ranirestat significantly improves nerve conduction velocity in diabetic polyneuropathy: a randomized double-blind placebo-controlled study in Japan. J Diabetes Investig. 2019;10(2):466-474.
Schemmel KE, Padiyara RS, D'Souza JJ. Aldose reductase inhibitors in the treatment of diabetic peripheral neuropathy: a review. J Diabetes Complications. 2010;24(5):354-360.
Hotta N, Toyota T, Matsuoka K, et al. Clinical efficacy of Fidarestat, a novel aldose reductase inhibitor, for diabetic peripheral neuropathy. Diabetes Care. 2001;24(10):1776-1782.
Hotta N, Akanuma Y, Kawamori R, et al. Long-term clinical effects of Epalrestat, an aldose reductase inhibitor, on diabetic peripheral neuropathy: the 3-year, multicenter, comparative aldose reductase inhibitor-diabetes complications trial. Diabetes Care. 2006;29(7):1538-1544.
Bril V, Buchanan RA, the AS-3201 Study Group. Aldose reductase inhibition by AS-3201 in sural nerve from patients with diabetic sensorimotor polyneuropathy. Diabetes Care. 2004;27(10):2369-2375.
Giannoukakis N. Ranirestat as a therapeutic aldose reductase inhibitor for diabetic complications. Expert Opin Investig Drugs. 2008;17(4):575-581.